BenevolentAI at the World Economic Forum Annual Meeting 2023

Join Joanna Shields, CEO of BenevolentAI in Davos at the 2023 WEF Annual Meeting 

The BenevolentAI team will be attending the World Economic Forum’s Annual Meeting in Davos in January 2023, as part of our participation in the Associate Partners Community, where we will be engaging with world leaders across sectors to discuss the impact that AI is making on healthcare and drug discovery.

Joanna Shields, CEO of BenevolentAI, will  join expert speakers across industry sectors, including biotech, pharmaceuticals and technology, at the following panels: 

  • World Economic Forum Panel Session: Biotech (R)evolution, on Wednesday, 18 January 16:15 - 17:00 PM CET (15:15 - 16:00 GMT). The livestream will be available here on the day of the panel.
  • Wellcome Trust Panel: Data and Digital Innovation for Climate and Health on Thursday 19 January 12:45 - 13.45 PM CET (11:45 - 12:45 GMT). The livestream will be available here on the day of the panel.

Joanna Shields

Chief Executive Officer

Joanna is passionate about creating technology that benefits humanity. She has spent her professional life building companies, products and platforms that have transformed markets and reshaped industries. She has been CEO of BenevolentAI since 2018 and has accelerated the company’s growth from a startup to a clinical-stage, AI-enabled drug discovery company. Joanna has over three decades of experience leading some of the world's best known technology companies, including Facebook, Bebo/Aol and Google. Prior to joining BenevolentAI, Joanna served in the UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser and UK Ambassador for Digital Industries. Joanna is the founder of the WeProtect Global Alliance, serves as the Co-Chair of the Global Partnership on Artificial Intelligence (GPAI) and is a Life Peer of the House of Lords.

More Posts

You Might Also Like

Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022